Harmony Biosciences Acquires Zynerba Pharmaceuticals

UCB to Acquire Zogenix for up to $1.9B

January 19, 2022

Pharmaceuticals

UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.

Harmony Biosciences Acquires Epygenix Therapeutics

April 30, 2024

Biotechnology

Harmony Biosciences has acquired Epygenix Therapeutics, adding a late-stage rare epilepsy franchise (including EPX-100 and EPX-200) to its CNS pipeline. Harmony paid $35 million in cash with up to $130 million in development/regulatory milestones and up to $515 million in potential sales milestones to complete the transaction.

Pfizer Acquires Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Pharmaceuticals

Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for approximately $11.6 billion (at $148.50 per share), bringing the migraine therapy NURTEC ODT (rimegepant), the zavegepant NDA program, and a CGRP-focused pipeline into Pfizer's Internal Medicine portfolio. Prior to closing, Biohaven spun off its non-CGRP assets into a separate publicly traded company, Biohaven Ltd., which Pfizer received a small pro rata stake in.

Ginkgo Bioworks Acquires Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) will acquire Zymergen in an all‑stock transaction valuing Zymergen at about $300 million; Zymergen stockholders will receive 0.9179 Ginkgo shares per Zymergen share and will own ~5.25% of the combined company. The acquisition is intended to integrate Zymergen's automation, software, and data‑science capabilities and biological assets into Ginkgo's horizontal cell‑programming platform to expand capacity, capabilities, and efficiency across multiple end markets.

Pacira BioSciences Acquires Flexion Therapeutics

October 11, 2021

Pharmaceuticals

Pacira BioSciences agreed to acquire Flexion Therapeutics for $8.50 per share in cash plus one contingent value right (CVR) worth up to $8.00 per share tied to sales and regulatory milestones. The deal adds Flexion's marketed non-opioid OA knee pain therapy ZILRETTA and its clinical-stage pipeline to Pacira's non-opioid pain management portfolio; the transaction was expected to close in Q4 2021 and to be accretive to Pacira's earnings.

MorphoSys Acquires Constellation Pharmaceuticals for $1.7B

June 2, 2021

Biotechnology

MorphoSys AG has agreed to acquire Constellation Pharmaceuticals for $34.00 per share in cash, valuing the transaction at approximately $1.7 billion. The deal strengthens MorphoSys' hematology-oncology pipeline by adding Constellation's mid- to late-stage candidates (pelabresib/CPI-0610 and CPI-0209) and is supported by a strategic funding partnership with Royalty Pharma that provides significant upfront and milestone funding.